Brofaromine (proposed brand name Consonar) is a reversible inhibitor of monoamine oxidase A (RIMA) developed by Ciba-Geigy for depression and anxiety disorders treatment. Brofaromine induces short, reversible and selective inhibition of brain MAO of type A in a dose-dependent manner in all brain regions. The largest decrease being found respectively in hippocampus, striatum and prefrontal cortex, regions having a rich monoaminergic innervation. Brofaromine also acts as a serotonin reuptake inhibitor, and its dual pharmacologic effects offered promise in the treatment of a wide spectrum of depressed patients while producing less severe anticholinergic side effects in comparison with older standard drugs like the tricyclic antidepressants. The compound was primarily researched in the treatment of depression and anxiety but its development was dropped before it was brought to market.